FDA Halts Studies Evaluating Pembrolizumab for Multiple Myeloma

Share this content:
The FDA determined that the available evidence shows the risks presented by pembrolizumab are greater than any potential benefit for patients with multiple myeloma.
The FDA determined that the available evidence shows the risks presented by pembrolizumab are greater than any potential benefit for patients with multiple myeloma.

The US Food and Drug Administration (FDA) has put a clinical hold on 2 clinical studies, KEYNOTE-183 (ClinicalTrials.gov Identifier: NCT02576977), KEYNOTE-185 (ClinicalTrials.gov Identifier: NCT02579863), and a partial clinical hold on KEYNOTE-023 (ClinicalTrials.gov Identifier: NCT02036502).1

The KEYNOTE trials were planned to evaluate the effectiveness of pembrolizumab, a PD-1 inhibitor, for the treatment of multiple myeloma.

KEYNOTE-183 was evaluating the effects of pomalidomide and dexamethasone with or without pembrolizumab in refractory or relapsed and refractory multiple myeloma. KEYNOTE-185 was evaluating lenalidomide and dexamethasone with or without pembrolizumab in newly diagnosed and treatment naïve multiple myeloma.

The decision to halt the studies was based on a review of data by the Data Monitoring Committee, which showed that more deaths occurred in the KEYNOTE-183 and KEYNOTE-185 trials for patients in the pembrolizumab arms.

The FDA determined that the available evidence shows the risks presented by pembrolizumab plus pomalidomide or lenalidomide are greater than any potential benefit for patients with multiple myeloma.

RELATED: Vaccines Targeting Multiple Myeloma Offer Promising Therapeutic Approach

Enrolled patients receiving investigational therapy will discontinue pembrolizumab in all halted trials.

No other trials of pembrolizumab are affected by this decision.

References

  1. Merck provides further update on three multiple myeloma studies evaluating Keytruda (pembrolizumab) in combination with pomalidomide or lenalidomide [news release]. Kenilworth, NJ: Business Wire; July 6, 2017. http://www.businesswire.com/news/home/20170705006004/en. Accessed July 6 2017. 

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters